Fertility: There are no data in humans to evaluate the effect of BETNOVATE-N fertility.
Pregnancy: There are limited data from the use of BETNOVATE-N in pregnant women.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development (see Pharmacology: Toxicology: Non-Clinical Information under Actions). The relevance of this finding to humans has not been established.
However, neomycin present in maternal blood can cross the placenta and may give rise to a theoretical risk of foetal toxicity (see Pharmacology: Toxicology: Non-Clinical Information under Actions). Thus use of BETNOVATE-N is not recommended in pregnancy.
Lactation: The safe use of BETNOVATE-N during lactation has not been established.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Thus use of BETNOVATE-N is not recommended in lactation.